Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, has received a medical device registration certificate from China's drug administration for its Transcutaneous Glomerular Filtration Rate Measurement Device.
The newly approved device consists of a host unit, a sensor, and a fixing sticker, and is designed for non-invasive measurement of glomerular filtration rate (GFR). GFR is a key indicator of kidney function.
The company's shares rose more than 1% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。